‘Udupi Helpline’ to transport excess food from wedding halls to the needy

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Mangaluru, May 17: Former health minister U T Khader demanded that the authorities carry out a scientific analysis of the five deaths that occurred due to Covid-19 in Dakshina Kannada. 

“The number of fatalities vis-à-vis the number of positive cases in the district is worrying, and the district administration and health department should not take the matter lightly. Lapses, if any, in dealing with the co-morbidity factors should be addressed, lest it become a major health challenge,” he warned.

Addressing reporters on Saturday, Khader, said only carrying out such types of analysis will help the health department combat the spread of the novel coronavirus in the future. “At present, the only data available with the health authorities here and in the state war room, is the number of people tested and number of positive cases,” Khader said.

“Any strategy to combat Covid-19 must be built around scientific analysis of causes of how the disease is spreading and to do so, concrete efforts must be made to find the source of the cluster at the First Neuro Hospital in Padil. A analysis of reasons that caused the deaths, will also come in handy for the authorities to prepare suitable advisories for the people, who in turn could take informed decisions,” Khader noted.

Chikkamagaluru, May 4: KSRTC resumed its service from Chikkamagaluru district headquarters to taluk centres amidst the lockdown to contain COVID-19 on Monday. Chikkamagaluru is in the green zone.

Hundreds of passengers travelled to Sringeri, Mudigere, Koppa and Kadur taluks since morning from the Chikkamagaluru city.

According to KSRTC Divisional Controller, passengers who wish to travel to taluk centres have to register half an hour prior to the journey. 

Sanitisers were placed in the bus stand in Chikkamagaluru to sanitise hands before boarding the buses.